No spam - just the good stuff

Subscribe to our newsletter

News

Drugs

Drusolv targets macular degeneration with statin therapy

It’s time to sit up and take notice of mitochondria

Life Biosciences in-licenses IP from new studies

New studies in Nature "open a new frontier in biotechnology and medicine," says Life Biosciences CEO Mehmood Khan.

New Buck Institute study is treasure trove for longevity research

Longevity Escape Velocity within 10 years?

“Adjust the immune system… de-age the brain”

AI to quantify senescent cell counts

Senolytic start-up gears up for clinical trials

Gerostate Alpha: “Our phenotype is lifespan”

CohBar announces preclinical collaboration with NIAID

“The major modulators of aging remain to be discovered”

New Longevity supplement targets cognitive decline

Senescence and the return of established splicing tech

Longevity companies to watch in 2021

Juvenescence (1): from strength to strength in R&D and investment firepower

A year in Longevity: progress perspectives

A year in Longevity: different perspectives

A year in Longevity: founders’ perspectives

A year in Longevity: science perspectives

VC and drug developer scale-up their incubator model

Eliminating senescent cells to improve heart attack recovery

Sigilon IPO raises $145m to address chronic diseases

Deep Longevity reveals highly-accurate aging clock

Calico’s memory-enhancing drug reverses age-related mental decline

BioAge CEO: “It’s all about the data.”

Silicon Valley is waking up to Longevity and senolytics

BioAge lands $90 million; gears up for clinical trials in 2021

Targeting inflammaging: the hidden “inflammapath” inside us

Found: the missing link in the Longevity ‘supply-chain’

AgelessRx and funding an IRB-approved rapamycin trial

Will rapamycin overtake metformin as a Longevity therapy?

Biogen Alzheimer’s drug closer to FDA approval

Find us here ...

Subscribe to our newsletter

© Copyright 2023 FIRST LONGEVITY Limited. All rights reserved. FIRST LONGEVITY

The information included in this website is for informational purposes only: its purpose is to promote a broad consumer understanding a knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website.

DISCLAIMER FOR U.S. BASED INVESTORS

The Agent of First Longevity Limited in the United States is Marco Polo Securities Inc, a non-affiliated broker-dealer registered with the US Securities and Exchange Commission. The activities of First Longevity Limited in the United States will be affected only to the extent permitted by Rule 15a-6 under the US Securities Exchange Act of 1934 and in accordance with the Services Agreement entered into between First Longevity Limited and Marco Polo Securities Inc with respect thereto. Contact at Marco Polo Securities is clientservices@mpsecurities.com; 1-347-745-6448.